National Bank of Greece completes buyback of 300,000 shares in August

Pavlos Mylonas CEO
Pavlos Mylonas CEO
0Comments

National Bank of Greece S.A. has reported the purchase of 300,000 of its own common shares between August 7 and August 14, 2025. The buyback is part of a program approved by shareholders at the Annual General Meeting on May 30, 2025, with further approval from the Single Supervisory Mechanism (SSM) of the European Central Bank granted on May 28, 2025.

The average price paid per share during this period was €13.1384, bringing the total cost to €3,941,515.00. Daily purchases ranged from €648,470.00 to €669,470.00.

According to the bank’s statement: “It is noted that in accordance with the resolutions of above-mentioned Annual General Meeting, the Bank intends to proceed with a subsequent cancellation of the above acquired own shares, in accordance with the relevant provisions regarding the time frame for the cancellation of Law 4548/2018.”

After these transactions, National Bank of Greece directly holds a total of 6,682,252 own shares. This represents approximately 0.73% of its share capital.

The announcement was made in line with (EU) Regulation No 596/2014 and other applicable regulations governing market disclosures within the European Union and Athens Exchange.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.